NovaDel Names Robert G. Savage, Former Worldwide Head of Johnson & Johnson's Pharmaceutical Group, to Board FLEMINGTON, N.J., March 1 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN BOARD: NVDL) has named Robert G. Savage, former worldwidechairman of Johnson & Johnson's Pharmaceutical Group, to its board of directors. Mr. Savage has been a top pharmaceutical executive for almost 20 years. As worldwide chairman of the Pharmaceuticals Group at J & J, he managed a business with annual netsales of more than $13 billion and 33,000 employees and was both a company officer and a member of the executive committee. At J & J, Mr. Savage led the acquisition and integration of Alza Pharmaceuticals, the largest and most aggressive of J & J's acquisitions to date. He also served J & J in the capacity of company group chairman and president of Ortho-McNeil Pharmaceuticals. Most recently, Mr. Savage was president for the General Therapeutics and Inflammation Business for Pharmacia Corporation where he held global responsibility for the inflammation portfolio. He has held multiple positions at Hoffmann-La Roche and Sterling Drug, leading marketing, business development and strategic planning. "Bob's desire to join NovaDel's board is a tremendous vote of confidence for our science and business strategy," said Gary A. Shangold, MD, NovaDel's CEO. "The depth and breadth of his experience will add significant strength to our planning and execution." Mr. Savage serves as a director for Noven Pharmaceuticals, a leader in the development of advanced drug delivery technologies; The Medicines Company, a pharmaceutical company focusing on the development and marketing of products that improve specialized care; and Vela Pharmaceuticals, a specialty pharma company focusing on pre-clinical research and clinical development. Mr. Savage received a BS in biology from Upsala College and an MBA from Rutgers University. About NovaDel Pharma Inc. NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the- counter drugs. The Company's proprietary lingual spray technology delivery system offers the patient (i) fast onset of action; (ii) improved drug safety by reducing the required drug dosage and reducing side effects; (iii) improved patient convenience and compliance; and (iv) enhanced dosage reliability. The Company plans to develop such products independently and through collaborative arrangements with majorpharmaceutical and biotech companies. Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein including, but not limited to, the ability to develop products (independently and through collaborative arrangements), and the ability to commercialize and obtain approval for products under development. Further, the Company operates in industries where securities may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's most recent Annual Report and Registration Statements, filed with the Securities and Exchange Commission. In assessing forward-looking statements contained herein, if any, the reader is urged to carefully read all cautionary statements contained in such filings. Contact: Barry C. Cohen Thomas Redington VP Business &New Product Development 203 222-7399 908 782-3431 x 2160 212 926-1733 NovaDel Pharma Inc. DATASOURCE: NovaDel Pharma Inc. CONTACT: Barry C. Cohen, VP Business & New Product Development of NovaDel Pharma Inc., +1-908-782-3431 ext. 2160; or Thomas Redington of Redington, Inc., +1-203-222-7399, +1-212-926-1733, or

Copyright